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Centre, Liverpool University, Liverpool, UKA B S T R A C TBackground: The cost of pharmaceuticals has increased rapidly in
Korea in recent years. Expenditure is likely to grow further with the
policy of expanding National Health Insurance coverage for the
following four disease areas: cerebrovascular and cardiovascular
disease, rare diseases, and cancer. Consequently, there is a need to
analyze the different components leading to this increased expendi-
ture as a basis for suggesting future reforms in Korea. Objective: To
quantify the impact of new and established drugs on the growth of
total drug spending in South Korea in recent years, specially focusing
on the differentiated components of drug spending. These include
treatment expansion and drug-mix effects (switching from cheaper
drugs to expensive ones and vice versa). Methods: A model was
proposed and used to assess the impact of both new and existing
drugs on changes in price, quantity, and drug mix over the 5-year
period in Korea from 2006 to 2010. The database used was the
National Health Insurance claims data, which covers about 97% of
the total population of Korea. Results: Overall drug spending
increased 1.43-fold from 2006 to 2010. Drug-mix effect (εt ¼ 1.32) was
the main factor contributing to increased drug spending, followed by
increased drug utilization (Qt ¼ 1.26). For existing drugs, treatment
expansion (QI) and drug-mix effect (εI) were measured at 1.28 and 1.24,
respectively, while those of new drugs were 1.02 (QN) and 1.03 (εN).ee front matter Copyright & 2015, International S
r Inc.
.1016/j.vhri.2015.01.004
st: The authors have indicated that they have no
ndence to: Hye-Young Kwon, Harvard School of PubTherefore, existing drugs have a much greater effect on drug spending
than do new drugs. According to the Anatomical Therapeutic Classi-
ﬁcation, drug spending rose most signiﬁcantly for the “sensory
organs” class of drugs (Et ¼ 1.78) followed by the “various” class (Et
¼ 1.68). For existing drugs in the sensory organs class (S), drug-mix
effect (εI) was measured at 0.96. This implies that expensive drugs
among existing drugs were replaced by cheaper ones. However, the
quantity prescribed (QI) substantially increased by 1.88-fold. New
drugs within this class that were more expensive than existing ones
were also prescribed (εN ¼ 1.09), further increasing drug expenditure
in Korea. Conclusions: We found contrasting results from previous
studies. The drug-mix effect and existing drugs made the largest
contribution to drug spending growth rather than new drugs. Policies
targeting drug mix, such as promoting cost-effective prescription and
rational use of drugs, including the use of cheaper cost generics
without compromising care, should be primarily considered to help
contain future drug expenditure.
Keywords: drug mix, established drugs, Korea, new drugs,
pharmaceutical expenditure.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Background
Pharmaceutical expenditure in South Korea is of particular
interest to health care system regulators. Over the last decade,
pharmaceutical expenditure in Korea increased 3.05-fold, while
total health expenditure increased 2.45-fold [1]. South Korea
spent 21.6% of its total health care expenditure on pharma-
ceuticals in 2010 [1]. This compares to Organization for Eco-
nomic Cooperation and Development countries, which spent
approximately 18% to 19% in 2009 [2]. However, in 2010,
pharmaceutical expenditure actually fell among some Euro-
pean Union member states [3]. This may be due to various
reforms and initiatives including stricter regulations for grant-
ing premium prices for new drugs and managing their entry,compulsory price cuts for existing drugs as well as a range of
demand-side measures to enhance the prescribing of low-cost
generics versus premium priced patented products in a class or
related class [4–8]. Aging populations, the increased prevalence
of chronic diseases, early adoption of expensive new drugs, and
doctors’ preference for prescribing high-cost drugs are often
cited as explanations for the growth of pharmaceutical expen-
diture in Korea [9,10]. This is set to continue with the policy to
expand National Health Insurance (NHI) coverage for four
disease areas—cerebrovascular and cardiovascular disease, rare
diseases, and cancer—that has been initiated by the new ruling
government [11].
Understanding which factors contribute to increased pharma-
ceutical expenditure is important to the Ministry of Health andociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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are responsible for the ﬁnancial management of NHI. A decom-
position analysis is often used to identify factors that contribute
to the increase in drug spending. Drug expenditure is usually
broken down into price, quantity, and drug mix using an index
method, such as Lasyperes, Paasches, and Fisher’s Ideal [12–26].
However, this methodology has been criticized because it could
not show the contribution of new drugs to the growth of drug
spending on each component of drug spending [24–26]. New drugs
are usually more expensive than incumbents (existing drugs) and
are consequently considered one of the key drivers of increases in
pharmaceutical expenditure [4,26,27]. Switching from cheaper to
more expensive drugs, the so-called drug-mix effect, is one of the
effects induced by the introduction of new drugs. Unless demand-
side measures are in place, new premium priced drugs could
replace cheaper incumbents, increasing the cost of treatment.
New drugs can also induce demand from those who could not be
treated appropriately with existing drug therapies, also referred to
as the “treatment expansion effect” [24,26–28].
In this study, we adopted a modiﬁed model of the decomposi-
tion analysis to assess the impact of new and established drugs on
the dynamics of drug cost, and to identify policy implications for
drug cost containment. Our analytical approach followed on from
the model of Gerdtham et al. [20], Gerdtham and Lundin [21,22],
and Addis and Magrini [23], but we aim to quantify drug-mix effect
and treatment expansion effect of both new and existing drugs,
respectively. The remainder of this article is organized as follows:
an overview of the Korean pharmaceutical market and the intro-
duction of new drugs; limitations of the decomposition analysis
that has been applied in previous studies; details of our approach
applied in this study; and conclusions drawn from our analysis.The Korean Pharmaceutical Market and the
Introduction of New Drugs
Drug expenditure in Korea has grown steeply after the imple-
mentation of the Separation of Drug Dispensing and Prescribing
policy in 2000 (Fig. 1). The market size for pharmaceuticals in
2011 was 16,402 trillion Korean won (US $14.325 billion), and
pharmaceutical expenditure by the NHI amounted to 81.9% of the
total market [29]. Most medicines available on the market were
consumed under the NHI scheme, although the number of
reimbursable drugs accounted for only 36.8% of all drugs
approved by the Ministry of Food and Drug Safety (Fig. 1).Fig. 1 – A glimpse of Korean pharmaceutical market. (A) Evoluti
portion of drug expenditures on the total health expenditure in
(2011). (B) Categorization of pharmaceuticals. Source: Korea Pha
POM, prescription-only medicine.Most new chemical entities (NCEs) were supplied by multina-
tional companies. Approximately 270 local companies supplied
generic drugs. Few local companies have the potential to develop
NCEs, and to date only 18 NCEs have been developed by local
companies [29].
The entry of new drugs is regulated by the Positive List System
and through price negotiations with the NHIS, the single payer. A
list of reimbursable drugs has been established in accordance
with the introduction of the Positive List System in 2007.
Subsequently, manufacturers have had to submit new drugs to
the Ministry of Food and Drug Safety for marketing approval, and
then to the Ministry of Health and Welfare to have a drug covered
by the NHI. The Drug Reimbursement Examination Committee,
part of the Health Insurance Review and Assessment Service,
then makes a ﬁnal decision. The criteria used to determine
reimbursement eligibility for new drugs include clinical useful-
ness, cost-effectiveness, budget impact, current status of reim-
bursement, and price in other countries [9,26,30–32]. Once a drug
has been assessed as reimbursable, the manufacturer must enter
into price negotiations with the NHIS before the drug can be
listed in the formulary. Since 2007, the average number of newly
introduced NCEs per year has dropped signiﬁcantly to 27.6, as
compared with 36.8 introduced between 2003 and 2006 [33].Limitations of Previous Decomposition Studies
Several studies have analyzed drug expenditure by separating it
into constituent elements, including price and quantity [12–26].
Gerdtham et al. [20] and Gerdtham and Lundin [21,22] examined
total drug expenditure in Sweden and emphasized the impor-
tance of residual (in other words, “drug mix”). Without changing
price and quantity, drug costs can increase as a result of switch-
ing from a cheaper drug to an expensive one in a class or related
class; this is the so-called drug-mix effect. They pointed out that
standard price indices do not reﬂect price changes resulting from
changes in drug consumption, especially changes resulting from
the introduction of new drugs. Several studies have examined the
drug-mix effect and identiﬁed it as major factor in drug spending
growth [20–24]. Dubois et al. [25] tried to quantify the impact of
new drugs by calculating price and volume factors including
changes in average price per day, the number of prescriptions per
person, and the number of days per prescription. Their results
indicate that prescribed days, prescriptions, and the number of
patients were signiﬁcant factors in expenditure growth.on of drug expenditures (in trillion Korean won [KRW]) and
South Korea (1995–2010). Source: Ministry of Health Welfare
rmaceutical Information Center [55]. OTC, over the counter;
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and Lundin [21,22], drug-mix (residual) and treatment expansion
effect (quantity increase) were measured. These effects were
attributable to both new and existing drugs. However, previous
studies did not distinguish these effects according to types of
drugs. In this study, we tried to quantify the impact of new drugs
on the components of drug cost. To do so, we proposed a
modiﬁed formula to segregate drug-mix and treatment expan-
sion effects by types of drugs: new and existing drugs. We then
applied this formula to investigate the factors contributing to
increased drug expenditure in the period from 2006 to 2010 in
South Korea, and quantiﬁed the effects of new and existing drugs
on changes in each component of drug cost. Finally, we have
made some suggestions for the authorities to consider when
deliberating future reforms. These are based on activities suc-
cessfully undertaken by European health authorities and health
insurance agencies.Table 1 – Decomposition analysis for total, incum-
bent, and new drug expenditures.
Category E P Q ε
Total 1.43 0.86 1.26 1.32
Incumbents 1.36 0.86 1.24 1.28
New drugs 1.05 1 1.02 1.03Methods
Data Collection
The data used in this study were obtained from the NHIS, which
covers about 97% of the Korean population. Total pharmaceutical
expenditure data from NHIS claims for the years 2006 to 2010
were used. More than 12,000 reimbursable products (about 4000
ingredients) were included for analysis. Each ingredient identiﬁed
in the NHIS data was matched to the Anatomical Therapeutic
Classiﬁcation (ATC) code [34]. The data were compiled on the
basis of ingredients. Medicines that incurred no charges in 2006
but appeared in the data in 2010 were regarded as new drugs. All
other listed drugs were considered incumbents. Quantity data
were collected as the minimum unit for each drug and delivery
system, for example, ampoules, tablets, patches, inhalers, and
capsules, because it proved impossible to calculate all utilization
in terms of deﬁned daily doses.
Study Methodology
Equation 1, ﬁrst proposed by Gerdtham et al. [20] and Gerdtham
and Lundin [21,22], shows changes in price (P), quantity (Q), and
drug mix (ε). The price change (P) is calculated by using the
Laspeyres index. According to this index, the price of new drugs
is not detected because their prices are not available at the base
period. Thus, the Laspeyres index (P) reﬂects only the price of
incumbents. The quantity ratio (Q) shows changes in the quanti-
ties of prescribed drugs including both new and incumbent drugs.
Drug mix (ε) indicates changes in the weighted average cost of
drugs attributable to both new and existing ones. Thus, quantity
change and drug mix are attributable to both new and existing
drugs. Consequently, we can measure drug-mix and treatment
expansion effects due to new drugs and existing drugs, sepa-
rately.
E¼
P
P1Q1P
P0Q0
¼Pt  Qt  εt¼
P
P1Q1P
P0Q0

P
Q1P
Q0

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P1Q1=
P
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 
P
P1Q0=
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Q0
  ð1Þ
Q0 is the quantity of drugs in 2006, Q1 is the quantity of drugs in
2010, P0 is the price of drug in 2006, P1 is the price of drug in 2010,
Pt is the change in price, Qt is the change in quantity, and εt is the
drug-mix effect.
Equation 2 is proposed to identify how new and incumbent
drugs affect the dynamics of drug cost. The growth in total drug
expenditure (Et) is attributed to new drugs (EN) and incumbents
(EI).
E¼
P
P1Q1P
P0Q0
¼EN  EI¼
X
PN1 Q
N
1 
P
PI1Q
I
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PI0Q
I
0
ð2ÞEN is growth in drug spending on new drugs, EI is growth in drug
expenditure on existing drugs, QN1 is quantity of new drugs in
2010, PN1 is price of new drugs in 2010, Q
I
0 is quantity of existing
drugs in 2006, Q I1 is quantity of existing drugs in 2010, P
I
0 is price
of existing drugs in 2006, and PI1 is price of existing drugs in 2010.
Equation 2 can then be rewritten as Eqs. 3 and 4:
E¼
P
P1Q1P
P0Q0
¼Pt  Qt  εt¼EN  PI  QI  εIð Þ ð3Þ
EN¼QN  εN¼
Qt
Q I
 εt
εI
ð4Þ
Pt is the price index between 2006 and 2010, PI is the price index of
existing drugs, PN is the price index of new drugs, Qt is quantity
change between 2006 and 2010, QI is quantity change of existing
drugs, QN is quantity change of new drugs, εt is drug-mix index
between 2006 and 2010, εI is drug-mix index of existing drugs, and
εN is drug-mix index of new drugs.
EN is constituted with QN and εN because Pt is equal to PI. If
EN 4 1, new drugs positively contribute to the increase in drug
spending. If EN ¼ 1, no impact from new drugs is observed,
signifying that there has been no introduction or penetration of
new drugs. QN indicates the treatment expansion effect of new
drugs, and εN indicates a shift in prescriptive patterns to expen-
sive new drugs. If one of these indices is greater than 1, new
drugs positively contributed to the growth of drug spending,
either by creating demands for new drugs or by a shift in
prescriptive patterns to expensive new drugs. This modiﬁed
equation (Eq. 3) can also detect the impact of existing drugs on
the component of drug cost through PI, QI, and εI.Results
Table 1 presents the quantiﬁed impact of new and incumbent
drugs on overall drug spending from 2006 to 2010. Overall
pharmaceutical expenditure increased by 43%. Drug mix (εt ¼
1.32) was the main contributing factor for increased drug spend-
ing, followed by quantity increase (Qt ¼ 1.26). The price index (Pt)
was 0.86, indicating that prices of existing drugs decreased by
14% in 2010, as compared to 2006. Existing drugs (EI ¼ 1.36) rather
than new drugs (EN ¼ 1.05) substantially affected the increase in
total drug spending. Approximately 83% of the increase in drug
expenditure was attributable to existing drugs. Quantity (QI) and
drug mix (εI) for existing drugs increased by 1.24- and 1.28-fold,
respectively. This indicates that manufacturers of existing drugs
have continued to expand their market and that more expensive
drugs have been used rather than cheaper alternatives.
New drugs have positively contributed to increased drug
spending, although minimally compared with established drugs.
In this regard, 17% of the increase in drug expenditure from 2006
to 2010 resulted from the use of new drugs. PN was set at 1
because the prices of new drugs were not available in 2006.
Consequently, price changes for new drugs could not be identi-
ﬁed within our equation. However, the drug-mix effect (εN)
induced by new drugs measured 1.03, which indicates a switch
from incumbents to marginally more expensive new drugs. The
Table 2 – Growth of drug expenditures for Anatomical Therapeutic Classiﬁcation groups.
Anatomical therapeutic class Overall Incumbents New drugs TPE (%)*
(A) Alimentary tract and metabolism 1.37 1.29 1.06 16.3
(B) Blood and blood-forming organs 1.59 1.54 1.04 9.0
(C) Cardiovascular system 1.53 1.44 1.06 19.7
(D) Dermatologicals 1.16 1.11 1.05 1.2
(G) Genitourinary system and sex hormones 1.39 1.25 1.11 2.4
(H) System hormonal preparations 1.36 1.34 1.02 0.8
(J) Antiinfective for systemic use 1.25 1.20 1.04 15.1
(L) Antineoplastic and immune-modulating agents 1.60 1.52 1.05 7.3
(M) Musculoskeletal system 1.22 1.17 1.05 7.1
(N) Nervous system 1.49 1.41 1.06 9.2
(P) Antiparasitics, insecticides, and repellents 1.03 1.03 1.00 0.1
(R) Respiratory system 1.49 1.42 1.05 5.7
(S) Sensory organs 1.78 1.58 1.13 2.6
(V) Various 1.68 1.64 1.02 3.5
* Percentage of total pharmaceutical expenditures (TPEs) in 2010.
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not signiﬁcant. Notably, it was found that the treatment expan-
sion and drug-mix effects were much larger for existing drugs
than for new drugs. This is different from the general belief that
new drugs are generally regarded as a key driver of increased
drug expenditure.
Table 2 presents the results according to ATC codes. Drug
spending has risen most signiﬁcantly in the “sensory organs”
class of drugs (Et ¼ 1.78), followed by the “various” class (Et ¼
1.68). Increases in expenditure for the various class (V), sensory
organs (S), antineoplastics and immune-modulating agents (L),
blood and blood-forming organs (B), cardiovascular system (C),
nervous system (N), and respiratory system (R) were greater than
the average growth rate (1.42). Growth in expenditure for all
groups was mainly attributed to incumbent drugs. New drugs
inﬂuenced expenditure most greatly for the “sensory organs”
class (EN ¼ 1.13). No new drugs were launched during the
observation period for class P (antiparasitics, insecticides, and
repellents). Although drug spending for class C drugs increased
by 1.53-fold, they represented the greatest percentage of total
drug spending.
A breakdown of drug expenditure factors for each ATC group,
and each type of drug, is presented in Table 3. Price indices for all
classes are less than 1, indicating a decrease in the prices ofTable 3 – Growth in drug expenditures for Anatomical Th
Anatomical therapeutic class Tota
P Q
(A) Alimentary tract and metabolism 0.88 1.1
(B) Blood and blood-forming organs 0.88 1.5
(C) Cardiovascular system 0.84 1.5
(D) Dermatologicals 0.86 1.2
(G) Genitourinary system and sex hormones 0.76 1.4
(H) System hormonal preparations 0.83 1.3
(J) Antiinfective for systemic use 0.85 1.1
(L) Antineoplastic and immune-modulating agents 0.84 1.5
(M) Musculoskeletal system 0.87 1.1
(N) Nervous system 0.87 1.1
(P) Antiparasitics, insecticides, and repellents 0.91 1.3
(R) Respiratory system 0.89 1.2
(S) Sensory organs 0.88 1.9
(V) Various 0.90 1.4existing drugs. A major factor in total drug expenditure growth
was increased quantities for all classes except ATC classes A, J, M,
N, and R, for which the drug-mix effect was a more signiﬁcant
factor. Drug mix for all classes increased (εt4 1) except for class P
(εt ¼ 0.86). The effects of new drugs equalled 1 for ATC class P.
This indicates that cheaper drugs in ATC class P were used
instead of expensive ones, without the introduction of new drugs.
For ATC class S, cheaper existing drugs replaced more expensive
ones (εI ¼ 0.96), but the quantity (QI) increased substantially (1.88
times). New drugs within this class, which were more expensive
than incumbents, were introduced and prescribed (εN ¼ 1.09),
which led to the increase in overall drug expenditure. Cheaper
antiparasitic drugs were increasingly used (εt ¼ 0.86) without the
introduction of new drugs. For ATC class S, drug quantities
substantially increased (QI ¼ 1.88) and cheaper existing drugs
were frequently used (εt ¼ 0.96). In addition, expensive new drugs
were introduced (QN ¼ 1.03 and εN ¼ 1.02). Overall, these factors
contributed to an increase in drug spending.Discussion
This study was initiated to assess the impact of new drugs as a
driver of increase in drug expenditure in Korea in recent years.erapeutic Classiﬁcation groups.
l Incumbents New drugs
ε P Q ε Q ε
6 1.34 0.88 1.15 1.28 1.01 1.05
0 1.20 0.88 1.43 1.22 1.05 0.98
0 1.22 0.84 1.44 1.19 1.04 1.02
6 1.07 0.86 1.24 1.04 1.02 1.03
2 1.29 0.76 1.30 1.27 1.09 1.01
9 1.18 0.83 1.38 1.16 1.00 1.01
3 1.30 0.85 1.13 1.25 1.00 1.04
4 1.23 0.84 1.54 1.18 1.00 1.05
2 1.26 0.87 1.11 1.21 1.01 1.04
8 1.45 0.87 1.17 1.39 1.01 1.04
1 0.86 0.91 1.31 0.86 1.00 1.00
6 1.32 0.89 1.23 1.29 1.03 1.02
4 1.04 0.88 1.88 0.96 1.03 1.09
6 1.27 0.90 1.46 1.25 1.00 1.02
Table 4 – Combination of supply- and demand-side initiatives among selected European countries and
their impact.
Country Class Initiative and outcomes
Denmark [42] ARBs  Delisting of all other ARBs other than losartan from the reimbursed list
 Patients could still be prescribed another ARB and have this reimbursed.
However, the prescribing physician has to justify the rationale and have this
accepted before other ARBs reimbursed—otherwise 100% co-payment
 The combination of supply- and demand-side measures in Denmark resulted
in a 77% reduction in ARB expenditure over the study period despite a 16%
increase in utilization, leading to estimated savings of more than 290 million
Danish kroner (€40 million) per annum
The Netherlands [38,41,43] PPIs and statins  Under the preference pricing policies, only the cheapest generics are
reimbursed, with patients having to cover the costs themselves for a
nonpreferred drug. This has resulted in generic omeprazole and simvastatin
at only 2% of prepatent loss prices
 This coupled with extensive multiple demand-side measures including
educational activities, prescribing targets, and physicians ﬁnancial incentives
to increase the prescribing of generics vs. patented products resulted in
reimbursed expenditure for the PPIs falling by 58% in 2010 vs. 2000 despite a
3-fold increase in utilization (deﬁned daily doses) and reimbursed
expenditure for the statins falling by 14% in 2010 vs. 2000 despite a 3.8-fold
increase in utilization, thereby saving considerable resources without
compromising care
Scotland [38,40,41,44,45] PPIs, statins, and ACEIs vs.
ARBs
 Transparency in the pricing of generics, coupled with transparency in rebates
offered to wholesalers and pharmacists, has resulted in prices of high-volume
generics being as low as 2%/3%–12% of prepatent loss prices
 Multiple demand-side measures including extensive educational activities,
prescribing targets, and physician ﬁnancial incentive schemes to increase the
prescribing of generics vs. patented products resulted in expenditure/1000
inhabitants/y for the PPIs in 2010 being 56% below 2001 levels despite a 3-fold
increase in utilization and reimbursed expenditure for the statins increased
by only 7% in 2010 compared with 2001 despite a 6.2-fold increase in
utilization. Without these measures, health authority spending on PPIs for
the same overall utilization would have been £159 million higher in 2010 in
Scotland for the 5.2 million population and £290 million for the statins
 Similar multiple demand-side measures vs. Portugal with its limited demand-
side measures to encourage the preferential prescribing of generic ACEIs
limited ARB prescribing to only 19% of total renin-angiotensin inhibitor drugs
in 2007 (DDD basis) vs. 44% in Portugal, leading to stable-reimbursed
expenditure between 2001 and 2007 vs. over 40% increase in Portugal
Sweden [38,39,41,46–48] PPIs, statins, and ARBs  Compulsory generic substitution with the lowest-price molecule has resulted
in prices for high-volume generics being 4% to 13% of originator prepatent
loss prices by 2009. More recently:
○ All pharmacies are obligated to offer patients the cheapest molecule
currently on the market (Anatomical Therapeutic Classiﬁcation Level 5)
when there are substitutable generic medicines available
○ There are regular monthly auctions for generics in Sweden, with the
manufacturer with the lowest price wining the auction. However,
manufacturers must be able to supply the whole market for the entire
period (typically 70%–80% of sales during the period)
○ Expected savings from the tendering process are estimated at 8 billion
SEK/y from 2011 onwards
 Multiple demand-side measures including extensive educational activities,
prescribing targets, and physician ﬁnancial incentives to increase the
prescribing of generics resulted in reimbursed expenditure for the PPIs
decreasing by 49% in 2007 vs. 2001 despite utilization increasing by 53%
during this period. Similar combined measures led to a 39% reduction in
statin expenditure in 2007 vs. 2001 despite a 3.2-fold increase in utilization
during this period
continued on next page
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Table 4 – continued
Country Class Initiative and outcomes
 Reimbursed expenditure (euros/1000 inhabitants/y) in Sweden was less than
one-tenth of that in Ireland in 2007 with its increased utilization of patented
PPIs and statins following generics as limited demand-side measures to
combat company activities (although more comorbid population)
 Similar demand-side measures including encouraging therapeutic
substitution of patented ARBs with losartan signiﬁcantly increased losartan
utilization in recent years. As a result, total single ARB expenditure fell by 26%
in recent years in Sweden despite a 16% increase in utilization. Separate
analyses suggest that care was not compromised at appropriate ARB doses
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DDD, deﬁned daily dose; PPI, proton pump inhibitor; SEK,
Swedish Krona.
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examined. To quantify these effects, we analyzed total pharma-
ceutical expenditure for South Korea over the 5-year period from
2006 to 2010. Previous studies [20–24] considered changes only in
price, quantity, and drug mix over time, without segregating the
observed changes by type of drug. However, these changes were
attributable to both new drugs and existing drugs. Our research
question was posed to distinguish the effects associated with
new and existing drugs. The previous model of Gerdtham et al.
[20] and Gerdtham and Lundin [21,22] was modiﬁed to calculate
the treatment expansion effect (QN) and drug-mix effect (εN). The
equation (Eq. 3) was also designed to measure the impact of
existing drugs in light of changes in price (PI), quantity (QI) and
drug mix (εI).
The results of this study indicate that existing drugs had a
greater effect on the growth of drug expenditure in recent years
in Korea than did the launch of new premium priced drugs.
Although treatment expansion and the drug-mix effect of new
drugs positively contributed to the increase in drug spending, the
quantiﬁed impact was minimal. Existing drugs substantially
contributed to increased pharmaceutical expenditure in recent
years. Prices for existing drugs decreased slightly over the period
(PI ¼ 0.86), but the drug-mix effect (εt ¼ 1.32) had the most
signiﬁcant impact, followed by quantity increase (Qt ¼ 1.26).
Given that increased drug volumes have long been claimed to
be the major factor contributing to the growth of Korean phar-
maceutical expenditure in recent years [17–19], this study
presents different results. Our ﬁndings indicate that the drug-
mix effect, for both existing and new drugs, had a greater impact
on the growth of drug expenditure than did increased volumes. In
addition, the growth of expenditure was mainly attributable to
existing drugs rather than new drugs. Prices for existing drugs
decreased in 2010 in all ATC classes when compared with 2006
prices. However, the overall drug-mix changed in a number of
classes, increasing overall drug expenditure. The drug-mix effect
was more signiﬁcant for ATC classes A, J, M, N, and R, with
increasing volumes the major factor for increased drug expendi-
ture in the other classes. This is perhaps not surprising because
cost-containment measures for pharmaceuticals in South Korea
have traditionally focused on enforced price cuts rather than
demand-side measures. Numerous repricing strategies have been
implemented, but the price decreases over the 5 years have not
been signiﬁcant [32,33,35]. The absence of policies that encourage
the use of cheaper drugs or more cost-effective prescriptive
practices results in the increased utilization of expensive drugs
facilitated by the considerable marketing activities of pharma-
ceutical companies [36]. Therefore, demand-side strategies to
address this should be prioritized to efﬁciently control the
increase in pharmaceutical expenditure in Korea with increased
coverage in four disease areas.Several policies enacted by the NHIS targeting new drugs,
such as the Positive List System and the price negotiation
procedure with the single payer, have acted as an entry barrier.
However, many of the strategies for drugs that are already listed
have focused only on cutting prices, and the effectiveness of
these strategies is debatable [37]. Because our ﬁndings suggest
that existing drugs rather than new drugs have a signiﬁcant
impact on the growth of drug expenditure, policies targeting both
cost-effective prescription practices and efﬁcient price controls
for existing drugs should be considered. There have been a
number of supply- and demand-side measures across Europe to
enhance the prescribing of low-cost generics in classes in which
all the drugs are seen as similar in all or nearly all patients [38–
42]. These initiatives have released considerable resources with-
out compromised care (summarized in Table 4), with the prod-
ucts in these classes seen as therapeutically similar at
appropriate doses demonstrated by meta analyses, registry stud-
ies as well as successful therapeutic switching programs [47–53].
A similar ﬁnding regarding losartan in Sweden was seen in
National Health Service Bury in England. Initially, there was no
change in the utilization of losartan post generics. This changed
signiﬁcantly following multiple interventions that were similar to
Sweden (Table 4) for patients with hypertension, with losartan
utilization increasing signiﬁcantly from 26% of all single ARBs to
65% 7 months later [49]. The savings were estimated at
eight times the cost of implementing this comprehensive pro-
gram [49].
We believe the exemplars in Denmark, The Netherlands,
Sweden, and the United Kingdom (National Health Service Bury
and Scotland) among a range of classes provide guidance for
Korea as it contemplates abolishing co-payments in high-
prevalence disease areas such as cardiovascular and cerebrovas-
cular diseases without appreciably increasing expenditures.
We accept that there are limitations with the study design.
These include our suggested methodology. However, we believe
that this approach is justiﬁed for the reasons we have given. We
also accept that we have not used deﬁned daily doses in our
analysis. However, other studies have used different units
including IMS units [54] as well as items dispensed [49]. Con-
sequently, we believe our ﬁndings are justiﬁed and provide
direction to the authorities in Korea.Conclusions
This study used a model to assess the impact of both new and
existing drugs on changes in price, quantity, and drug mix over
the 5-year period in Korea from 2006 to 2010. Contrary to the
results of previous studies, our ﬁndings indicate that the drug-
mix effect and existing drugs contributed most to the growth in
V A L U E I N H E A L T H R E G I O N A L I S S U E S 6 C ( 2 0 1 5 ) 1 4 – 2 120pharmaceutical expenditure. Policies targeting drug mix are not
sufﬁciently implemented in South Korea and reforms to encour-
age the prescribing use of cost-effective drugs within a class
should be emphasized. Measures can also include initiatives to
reduce drug volumes where these are considered inappropriately
high.Acknowledgments
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